Mercaptopurine

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc ATC codes: L01BB02

Indication	Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: 2A60.0
INN	Mercaptopurine
Medicine type	Chemical agent
List type	Complementary
Formulations	**Oral > Liquid:** 20 mg per mL (EMLc) **Oral > Solid:** 50 mg tablet
EML status history	First added in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Cancer
Wikipedia	Mercaptopurine
DrugBank	Mercaptopurine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of mercaptopurine (oral liquid 20 mg/mL) to the EMLc.